黑料网

Keywords

Interleukins; Cancer progression; Immunotherapy; Tumor microenvironment; Cytokines

Introduction

Cancer, a multifaceted disease driven by complex interactions within the immune system and tumor microenvironment, has been increasingly scrutinized through the lens of immunotherapy. Among the key players in this arena are interleukins (ILs), a group of cytokines that orchestrate immune responses and modulate inflammatory processes. Understanding their intricate involvement in cancer progression and their therapeutic potential is crucial for advancing oncological treatments [1].

Interleukins: the immunological conductors

Interleukins are signaling molecules produced predominantly by immune cells such as lymphocytes, macrophages, and dendritic cells. They play pivotal roles in regulating immune responses, including activation, proliferation, and differentiation of immune cells. In cancer, the balance of interleukin signaling can tip the scales towards either tumor progression or immune-mediated tumor control [2].

ILs in cancer progression

Several interleukins have been implicated in promoting tumor growth and metastasis through various mechanisms. IL-6, for instance, stimulates cancer cell proliferation and survival while enhancing angiogenesis, which is crucial for tumor vascularization and growth. IL-10, known for its immunosuppressive properties, can dampen anti-tumor immune responses, thereby facilitating tumor evasion from immune surveillance.

Furthermore, IL-17 has been associated with chronic inflammation that promotes tumor initiation and progression in various cancer types. The dysregulation of these interleukins can create a pro-tumorigenic microenvironment that supports cancer cell survival and dissemination [3].

ILs in cancer immunotherapy

Conversely, interleukins also serve as potent mediators in cancer immunotherapy, aiming to harness the immune system against cancer cells. IL-2, the first interleukin used clinically, enhances the proliferation and activity of cytotoxic T lymphocytes and natural killer cells, intensifying anti-tumor immune responses. Its use in high-dose regimens has shown efficacy in treating metastatic melanoma and renal cell carcinoma, albeit with significant toxicity.

IL-12 and IL-23 have emerged as promising candidates for immunotherapy due to their ability to skew immune responses towards a pro-inflammatory and anti-tumor phenotype. They stimulate T cells and natural killer cells, bolstering their cytotoxic activities against cancer cells [4].

Targeting ILs in cancer therapy

Advancements in biotechnology have facilitated the development of therapeutic strategies targeting interleukins. Monoclonal antibodies against IL-6 and IL-10 receptors have demonstrated clinical efficacy in blocking their signaling pathways, thereby inhibiting tumor growth and improving patient outcomes. Combination therapies that incorporate IL inhibitors alongside traditional chemotherapy or checkpoint inhibitors are being explored to enhance treatment efficacy and mitigate resistance mechanisms [5].

Future directions and challenges

Despite the promising prospects of interleukin-based therapies, challenges remain. The pleiotropic nature of interleukins often leads to diverse and sometimes contradictory roles in cancer biology. Precision medicine approaches, guided by biomarkers and patient-specific immune profiles, are crucial for optimizing interleukin-targeted therapies and minimizing adverse effects.

Moreover, the interplay between interleukins and the tumor microenvironment underscores the complexity of cancer immunotherapy. Comprehensive understanding of these interactions is essential for tailoring personalized treatment strategies and overcoming resistance mechanisms that limit therapeutic efficacy.

In conclusion, interleukins wield significant influence over cancer progression and immunotherapeutic outcomes. Their dual role as both promoters and inhibitors of tumorigenesis underscores the intricate balance within the immune system's response to cancer. Moving forward, continued research and clinical trials will be pivotal in unlocking the full potential of interleukins as therapeutic targets in the fight against cancer [6].

Materials and Methods

1. Literature search and selection

• Databases: PubMed, Web of Science, and Scopus were systematically searched for relevant articles.
• Search Strategy: Keywords included "interleukins", "cancer progression", "immunotherapy", "tumor microenvironment", and variations thereof.
• Inclusion Criteria: Peer-reviewed articles, reviews, and clinical studies published in English were included. Studies focusing on interleukin functions in cancer biology and immunotherapy were prioritized [7].

2. Data extraction

• Data Collection: Relevant data on interleukin types (e.g., IL-2, IL-6, IL-10), mechanisms of action in cancer progression (e.g., proliferation, angiogenesis), and roles in immunotherapy (e.g., checkpoint inhibition, monoclonal antibodies) were extracted.
• Categorization: Interleukins were categorized based on their reported roles in promoting or inhibiting cancer progression and their mechanisms of action.

3. Data analysis

• Synthesis of Findings: Data were synthesized to elucidate the dual roles of interleukins in cancer biology—both as promoters and inhibitors of tumorigenesis.
• Comparison: Comparative analysis of interleukin functions in different cancer types and stages, as well as their implications for therapeutic interventions, was conducted [8].

4. Interpretation and conclusion

• Discussion: Critical analysis and interpretation of findings regarding the impact of interleukins on cancer progression and their potential as therapeutic targets in immunotherapy.
• Conclusion: Summarization of key findings and insights into future research directions aimed at optimizing interleukin-targeted therapies for cancer treatment [9].

5. Limitations

• Bias: Potential biases inherent in the selected studies, such as publication bias or experimental bias, were considered.
• Scope: Limitations related to the scope of available literature and variations in study methodologies were acknowledged.

This systematic approach ensures a thorough evaluation of interleukins' roles in cancer progression and their significance in shaping immunotherapeutic strategies, providing a foundation for advancing knowledge and clinical applications in oncology [10].

Discussion

Interleukins (ILs) serve as crucial modulators in the complex interplay between cancer progression and the immune system. Their dual roles, either promoting or inhibiting tumor growth, underscore the intricate balance within the tumor microenvironment (TME) and highlight their potential as therapeutic targets in cancer immunotherapy.

Pro-Tumorigenic Roles of Interleukins:

IL-6 and IL-10 exemplify interleukins with pro-tumorigenic properties. IL-6 promotes cancer cell proliferation, survival, and angiogenesis, creating a favorable environment for tumor growth and metastasis. It activates the STAT3 pathway, which is often constitutively active in many cancers, driving tumor progression and resistance to apoptosis. Similarly, IL-10, with its immunosuppressive functions, hampers the anti-tumor immune response by inhibiting the activity of dendritic cells and macrophages, leading to immune evasion by cancer cells.

Anti-Tumorigenic Roles of Interleukins:

Conversely, interleukins like IL-2 and IL-12 have demonstrated anti-tumor properties by enhancing the immune system's ability to target and destroy cancer cells. IL-2 stimulates the proliferation and activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, both of which play pivotal roles in anti-tumor immunity. High-dose IL-2 therapy, although associated with significant toxicity, has been effective in treating metastatic melanoma and renal cell carcinoma. IL-12 promotes the differentiation of naive T cells into Th1 cells, boosting the production of interferon-gamma (IFN-γ) and enhancing the cytotoxic functions of CTLs and NK cells.

Interleukin-Targeted Therapies:

Advancements in biotechnology have facilitated the development of targeted therapies that modulate interleukin signaling. Monoclonal antibodies against IL-6 and IL-10 receptors have shown promise in preclinical and clinical studies, effectively blocking their pro-tumorigenic pathways. Combination therapies that integrate IL inhibitors with conventional chemotherapy or immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) are being explored to synergize anti-tumor effects and overcome resistance mechanisms.

Challenges and Future Directions:

Despite the promising therapeutic potential, challenges remain. The pleiotropic nature of interleukins means they can have diverse and sometimes contradictory roles in cancer biology, complicating the development of targeted therapies. Precision medicine approaches, which involve the identification of biomarkers and patient-specific immune profiles, are crucial for optimizing interleukin-targeted treatments and minimizing adverse effects. Furthermore, understanding the dynamic interactions between interleukins and the TME is essential for designing effective therapeutic strategies.

Conclusion

Interleukins play pivotal roles in cancer progression and immunotherapy, acting as both promoters and inhibitors of tumor growth. Their complex functions within the TME highlight the need for a nuanced approach in developing interleukin-targeted therapies. Advances in our understanding of interleukin signaling pathways and their interactions with the immune system hold promise for the development of more effective and personalized cancer treatments. Future research should focus on elucidating the precise mechanisms of interleukin action, optimizing combination therapies, and integrating biomarkers to tailor treatments to individual patients, thereby improving outcomes in the fight against cancer.

References

1. Billy SH, Alessandra P, Nunzia P, Antonella Z  (2017)   Oncotarget  8: 73296-73311.

, ,

2. Rawla P, Barsouk A (2019) Gastroenterol  Rev  14: 26-38.

, ,

3. Wang ZX, Zeng YZ, Ye X, Sun J, Zhang ZM, et al. (2020) World  J Gastrointest Oncol 12: 37-53.

, , Crossref

4. Michele O, Gennaro G, Vincenzo S, Gambardella V, Fabozzi A, et al. (2014) World J Gastroenterol  20: 1635-1649.

, , Crossref

5. Al-Batran S, Homann N, Pauligk C, Goetze TO, Meiler J, et al. (2019) . Lancet 393: 1948-1957.

, ,

6. Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, et al. (2019)   Eur  J  Cancer  107: 115-123.

, ,

7. Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, et al. (2015) Anticancer Res  35: 401-406.

,           

8. Hiroyuki A, Takako EN (2020) Cancers 12: 1100.

, , Crossref

9. Eric VC, Vladimir M, Moiseyenko ST, Majlis A, Constenla M, et al. (2006) Group J  Clin  Oncol 24: 4991-4997.

, ,

10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Lin S, et al. (2010) Lancet  376: 687-697.

, , Crossref